Cargando…

Minimal residual disease in childhood B Lymphoblastic Leukemia and its correlation with other risk factors

OBJECTIVE: To determine frequency of post induction and post consolidation minimal residual disease (MRD) in pediatric B-lymphoblastic leukemia (B-ALL) patients and its association with clinical risk factors. METHODS: This is a retrospective, cross sectional study carried out at the Indus Hospital o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Meraj, Fatima, Jabbar, Naeem, Nadeem, Kishwer, Taimoor, Momal, Mansoor, Neelum
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Professional Medical Publications 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6943114/ https://www.ncbi.nlm.nih.gov/pubmed/31933602 http://dx.doi.org/10.12669/pjms.36.ICON-Suppl.1721

Ejemplares similares

Central Nervous System Involvement in Childhood Acute Lymphoblastic Leukemia: An Analysis of Day-One Versus Day-Eight Lumbar Punctures in Remission Induction Therapy
por: Arshad, Uzma, et al.
Publicado: (2021)

Infantile B-lymphoblastic leukemia: a case series and review of the literature
por: Mansoor, Neelum, et al.
Publicado: (2023)

Spectrum of hemoglobinopathies with hematological and biochemical profile: A five year experience from a tertiary care hospital
por: Mansoor, Neelum, et al.
Publicado: (2022)

Distribution of subtypes and immunophenotypic characterization of 1379 cases of paediatric acute leukaemia
por: Jamal, Saba, et al.
Publicado: (2021)

Current Strategies for the Detection of Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia
por: Rocha, Juliana Maria Camargos, et al.
Publicado: (2016)

Sources of error in measurement of minimal residual disease in childhood acute lymphoblastic leukemia
por: Latham, Sue, et al.
Publicado: (2017)

Circulating microRNAs as minimal residual disease biomarkers in childhood acute lymphoblastic leukemia
por: Rzepiel, Andrea, et al.
Publicado: (2019)

Minimal Residual Disease Detection in Acute Lymphoblastic Leukemia
por: Kruse, Aaron, et al.
Publicado: (2020)

Validation of Minimal Residual Disease as Surrogate Endpoint for Event-Free Survival in Childhood Acute Lymphoblastic Leukemia
por: Galimberti, Stefania, et al.
Publicado: (2018)

TFDP3 confers chemoresistance in minimal residual disease within childhood T-cell acute lymphoblastic leukemia
por: Chu, Ming, et al.
Publicado: (2016)

Clinical Significance of Minimal Residual Disease at the End of Remission Induction Therapy in Childhood Acute Lymphoblastic Leukemia
por: Jovanovska, Aleksandra, et al.
Publicado: (2019)

The Effects of Voriconazole on Metabolism of All-Trans Retinoic Acid in the Treatment of Acute Promyelocytic Leukemia: A Case Report
por: Hashmi, Yusra, et al.
Publicado: (2021)

Minimal Residual Disease in Acute Lymphoblastic Leukemia: Technical and Clinical Advances
por: Della Starza, Irene, et al.
Publicado: (2019)

Minimal Residual Disease in Adult Acute Lymphoblastic Leukemia: Egyptian Experience
por: Ibrahim, Rasha Ibrahim, et al.
Publicado: (2022)

Measurable residual disease in childhood B-cell acute lymphoblastic leukemia
por: Gale, Robert Peter
Publicado: (2022)

Minimal Residual Disease in Acute Lymphoblastic Leukemia: Current Practice and Future Directions
por: Contreras Yametti, Gloria Paz, et al.
Publicado: (2021)

Optimizing Molecular Minimal Residual Disease Analysis in Adult Acute Lymphoblastic Leukemia
por: Della Starza, Irene, et al.
Publicado: (2023)

The utility of multiparametric flow cytometry for the detection of minimal residual disease in acute lymphoblastic leukemia
por: Cunha, Fernanda Gonçalves Pereira, et al.
Publicado: (2012)

Minimal residual disease in acute lymphoblastic leukemia: technical aspects and implications for clinical interpretation
por: Kim, In-Suk
Publicado: (2020)

Quantitative monitoring of minimal residual disease in childhood acute lymphoblastic leukemia using TEL‐AML1 fusion transcript as a marker
por: Zhao, Xiaoxi, et al.
Publicado: (2019)

Metabolomic profiling identifies pathways associated with minimal residual disease in childhood acute lymphoblastic leukaemia
por: Schraw, Jeremy M., et al.
Publicado: (2019)

Transcriptome Analysis of Minimal Residual Disease in Subtypes of Pediatric B Cell Acute Lymphoblastic Leukemia
por: Sitthi-amorn, Jitsuda, et al.
Publicado: (2015)

Proposal for the standardization of flow cytometry protocols to detect minimal residual disease in acute lymphoblastic leukemia
por: Ikoma, Maura Rosane Valério, et al.
Publicado: (2015)

Genotype-Specific Minimal Residual Disease Interpretation Improves Stratification in Pediatric Acute Lymphoblastic Leukemia
por: O’Connor, David, et al.
Publicado: (2018)

Testing for minimal residual disease in adults with acute lymphoblastic leukemia in Europe: a clinician survey
por: Pigneux, Arnaud, et al.
Publicado: (2018)

Inherited GATA3 variant associated with positive minimal residual disease in childhood B‐cell acute lymphoblastic leukemia via asparaginase resistance
por: Li, Chunjie, et al.
Publicado: (2021)

Minimal Residual Disease-Based Risk Stratification in Chinese Childhood Acute Lymphoblastic Leukemia by Flow Cytometry and Plasma DNA Quantitative Polymerase Chain Reaction
por: Cheng, Suk Hang, et al.
Publicado: (2013)

Minimal residual disease detection in Tunisian B-acute lymphoblastic leukemia based on immunoglobulin gene rearrangements
por: Besbes, S., et al.
Publicado: (2017)

The Microbiome in Childhood Acute Lymphoblastic Leukemia
por: Oldenburg, Marina, et al.
Publicado: (2021)

Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913
por: Chiaretti, Sabina, et al.
Publicado: (2020)

Prognostic Significance and Treatment Implications of Minimal Residual Disease Studies in Philadelphia-Negative Adult Acute Lymphoblastic Leukemia
por: Spinelli, Orietta, et al.
Publicado: (2014)

Clinicians’ Perspectives on Cure in Adult Patients with Acute Lymphoblastic Leukemia with Minimal Residual Disease: A Delphi Study
por: Gidman, Wendy, et al.
Publicado: (2019)

P366: ARE MINIMAL RESIDUAL DISEASE MEASUREMENTS AFTER CONSOLIDATION THERAPY USEFUL IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA?
por: Stutterheim, Janine, et al.
Publicado: (2023)

Cytomegalovirus Reactivation in Patients With Acute Lymphoblastic Leukemia in Non-transplant Setting
por: Abbas, Mansoor, et al.
Publicado: (2022)

Obesity in patients with acute lymphoblastic leukemia in childhood
por: Iughetti, Lorenzo, et al.
Publicado: (2012)

Childhood acute lymphoblastic leukemia with hyperleukocytosis at presentation
por: Kong, Seom Gim, et al.
Publicado: (2014)

Epigenetic Priming in Childhood Acute Lymphoblastic Leukemia
por: Raboso-Gallego, Javier, et al.
Publicado: (2019)

Dyslipidemia at diagnosis of childhood acute lymphoblastic leukemia
por: Mogensen, Pernille Rudebeck, et al.
Publicado: (2020)

Synthesized evidence for childhood acute lymphoblastic leukemia
por: Onyije, Felix M., et al.
Publicado: (2023)

Improving the Identification of High Risk Precursor B Acute Lymphoblastic Leukemia Patients with Earlier Quantification of Minimal Residual Disease
por: Karsa, Mawar, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_7gbkigivamq61ts4m1b2glq0bo